JP2010536797A - 眼の疾患または状態を治療するための製剤 - Google Patents

眼の疾患または状態を治療するための製剤 Download PDF

Info

Publication number
JP2010536797A
JP2010536797A JP2010521229A JP2010521229A JP2010536797A JP 2010536797 A JP2010536797 A JP 2010536797A JP 2010521229 A JP2010521229 A JP 2010521229A JP 2010521229 A JP2010521229 A JP 2010521229A JP 2010536797 A JP2010536797 A JP 2010536797A
Authority
JP
Japan
Prior art keywords
rapamycin
liquid formulation
variations
less
eye
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2010521229A
Other languages
English (en)
Japanese (ja)
Other versions
JP2010536797A5 (enExample
Inventor
ドール，フィリップ，ジェイ．エム．
ムドゥンバ，スリーニバス
ニバッジオリ，テーリー
ウェーバー，デイビッド，エー．
ファルーク，シディク
タクハー，スディープ，カウアー
Original Assignee
マクサイト， インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by マクサイト， インコーポレイテッド filed Critical マクサイト， インコーポレイテッド
Publication of JP2010536797A publication Critical patent/JP2010536797A/ja
Publication of JP2010536797A5 publication Critical patent/JP2010536797A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A61K9/0051—Ocular inserts, ocular implants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7007—Drug-containing films, membranes or sheets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Ophthalmology & Optometry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Inorganic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dispersion Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Endocrinology (AREA)
  • Mycology (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2010521229A 2007-08-16 2008-08-18 眼の疾患または状態を治療するための製剤 Pending JP2010536797A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US96525807P 2007-08-16 2007-08-16
US96528207P 2007-08-16 2007-08-16
PCT/US2008/073520 WO2009023877A2 (en) 2007-08-16 2008-08-18 Formulations for treatment of ocular diseases or conditions

Publications (2)

Publication Number Publication Date
JP2010536797A true JP2010536797A (ja) 2010-12-02
JP2010536797A5 JP2010536797A5 (enExample) 2013-07-25

Family

ID=40351498

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2010521229A Pending JP2010536797A (ja) 2007-08-16 2008-08-18 眼の疾患または状態を治療するための製剤

Country Status (6)

Country Link
EP (1) EP2187743B1 (enExample)
JP (1) JP2010536797A (enExample)
KR (1) KR20100055482A (enExample)
CN (1) CN101827523A (enExample)
ES (1) ES2507078T3 (enExample)
WO (1) WO2009023877A2 (enExample)

Cited By (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016148228A1 (ja) * 2015-03-18 2016-09-22 参天製薬株式会社 徐放性医薬組成物
JP2016175884A (ja) * 2015-03-23 2016-10-06 国立大学法人大阪大学 びまん性神経線維腫用の外用薬
JP2017057199A (ja) * 2015-09-18 2017-03-23 参天製薬株式会社 角膜真菌症の予防または治療剤
JPWO2017038612A1 (ja) * 2015-08-28 2018-06-14 日本化薬株式会社 ラパマイシン又はその誘導体を含有する医薬組成物
JP2019526532A (ja) * 2016-06-30 2019-09-19 デュレクト コーポレーション デポー製剤
JP2020504182A (ja) * 2017-01-06 2020-02-06 パルヴェラ セラピューティクス エルエルシー ｍＴＯＲ阻害剤の無水組成物およびその使用方法
JPWO2021132565A1 (enExample) * 2019-12-26 2021-07-01
JP2021530463A (ja) * 2018-07-02 2021-11-11 パルヴェラ セラピューティクス、インク． ｍＴＯＲ阻害剤の無水組成物および使用方法
RU2842860C1 (ru) * 2019-12-26 2025-07-02 Сантен Фармасьютикал Ко., Лтд. Водная суспензионная композиция, содержащая сиролимус или его соль

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2564843B1 (en) 2005-06-01 2018-12-26 Bioelectron Technology Corporation Redox-active therapeutics for treatment of mitochondrial diseases and other conditions and modulation of energy biomarkers
EP1986636B1 (en) 2006-02-22 2013-04-24 Edison Pharmaceuticals, Inc. Phenol and 1,4-benzoquinone derivatives for use in the treatment of mitochondrial diseases
PL2424495T3 (pl) 2009-04-28 2018-06-29 Bioelectron Technology Corporation Leczenie dziedzicznej neuropatii nerwów wzrokowych lebera i dominującego zaniku nerwu wzrokowego chinonami tokotrienolu
CA2783699C (en) 2009-12-08 2019-01-15 Case Western Reserve University Primary amine compounds for treating ocular disorders
HK1201196A1 (en) * 2011-10-13 2015-08-28 Aerpio Therapeutics, Inc. Treatment of ocular disease
US8912215B2 (en) 2011-12-13 2014-12-16 Everon Biosciences, Inc. Rapamycin composition
CN103239399B (zh) * 2013-05-30 2016-06-29 山东兴瑞生物科技有限公司 一种西罗莫司纳米混悬剂及其制备方法
KR101674457B1 (ko) * 2013-11-04 2016-11-09 아주대학교산학협력단 다사티닙 또는 이의 약학적으로 허용되는 염을 유효성분으로 포함하는 혈관 투과성 관련 질환의 예방 또는 치료용 약학적 조성물
CN107205929B (zh) * 2015-02-02 2022-06-24 参天制药股份有限公司 多泡沫体及其眼睑施用
EP3463349B1 (en) * 2016-05-25 2021-08-04 Santen Pharmaceutical Co., Ltd. Use of sirolimus to treat exudative age-related macular degeneration with persistent edema
AU2017388230A1 (en) * 2016-12-27 2019-08-15 University Of Utah Research Foundation Intraocular drug delivery device and associated methods
EP3501496A1 (en) * 2017-12-22 2019-06-26 Cosmo Technologies Ltd. Liquid delivery composition
US11648197B2 (en) 2018-06-28 2023-05-16 Arx, Llc Dispensing method for producing dissolvable unit dose film constructs
CN109431997B (zh) * 2018-12-20 2021-06-04 武汉科福新药有限责任公司 一种雷帕霉素局部注射制剂及其制备方法
CN112263670A (zh) * 2020-10-22 2021-01-26 温州医科大学 硼替佐米及其制剂在制备治疗脉络膜新生血管性相关疾病药物上的应用及滴眼液制备方法
EP4355349A4 (en) * 2021-06-15 2025-04-16 ONL Therapeutics, Inc. Methods and compositions for treating eye diseases and disorders
CN115337263B (zh) * 2022-08-09 2023-10-03 江苏汉晨药业有限公司 一种盐酸洛美沙星滴眼液
CN115813863A (zh) * 2022-12-15 2023-03-21 广州因明生物医药科技股份有限公司 一种可自发团聚的微球及其制备方法
CN119258216A (zh) * 2023-07-05 2025-01-07 沈阳兴齐眼药股份有限公司 眼用药物组合物、其制备方法、含其的眼用药盒及应用

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003007944A1 (en) * 2001-07-20 2003-01-30 Qlt, Inc. Treatment of macular edema with photodynamic therapy
JP2006511475A (ja) * 2002-09-18 2006-04-06 トラスティーズ オブ ザ ユニバーシティ オブ ペンシルベニア 脈絡膜新生血管症の抑制方法
US20060258698A1 (en) * 2005-02-09 2006-11-16 Sreenivasu Mudumba Liquid formulations for treatment of diseases or conditions
JP2007509931A (ja) * 2003-10-30 2007-04-19 セルジーン・コーポレーション 黄斑変性症を治療するための組成物及び方法

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7083802B2 (en) * 2003-07-31 2006-08-01 Advanced Ocular Systems Limited Treatment of ocular disease
US20060182783A1 (en) * 2004-04-30 2006-08-17 Allergan, Inc. Sustained release intraocular drug delivery systems
US20060216288A1 (en) * 2005-03-22 2006-09-28 Amgen Inc Combinations for the treatment of cancer

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003007944A1 (en) * 2001-07-20 2003-01-30 Qlt, Inc. Treatment of macular edema with photodynamic therapy
JP2006511475A (ja) * 2002-09-18 2006-04-06 トラスティーズ オブ ザ ユニバーシティ オブ ペンシルベニア 脈絡膜新生血管症の抑制方法
JP2007509931A (ja) * 2003-10-30 2007-04-19 セルジーン・コーポレーション 黄斑変性症を治療するための組成物及び方法
US20060258698A1 (en) * 2005-02-09 2006-11-16 Sreenivasu Mudumba Liquid formulations for treatment of diseases or conditions

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
JPN6013016531; Ｃｌｉｎｉｃａｌ　Ｉｎｔｅｒｖｅｎｔｉｏｎｓ　ｉｎ　Ａｇｉｎｇ １，　４, 2006, ｐ．４５１-４６６ *
JPN6013016534; Ｏｐｈｔｈａｌｍｏｌｏｇｙ １１３, 2006, ｐ．１７０６-１７１２ *
JPN6013016538; Ｏｐｈｔｈａｌｍｏｌｏｇｅ １０３, 2006, ｐ．４７１-４７５ *
JPN6013016542; Ａｎｇｉｏｇｅｎｅｓｉｓ １０, 200703, ｐ．１４１-１４８ *

Cited By (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11090296B2 (en) 2015-03-18 2021-08-17 Santen Pharmaceutical Co., Ltd. Sustained-release pharmaceutical composition
WO2016148228A1 (ja) * 2015-03-18 2016-09-22 参天製薬株式会社 徐放性医薬組成物
JP2016175884A (ja) * 2015-03-23 2016-10-06 国立大学法人大阪大学 びまん性神経線維腫用の外用薬
JPWO2017038612A1 (ja) * 2015-08-28 2018-06-14 日本化薬株式会社 ラパマイシン又はその誘導体を含有する医薬組成物
JP2017057199A (ja) * 2015-09-18 2017-03-23 参天製薬株式会社 角膜真菌症の予防または治療剤
JP2019526532A (ja) * 2016-06-30 2019-09-19 デュレクト コーポレーション デポー製剤
JP2022088568A (ja) * 2016-06-30 2022-06-14 デュレクト コーポレーション デポー製剤
JP7051721B2 (ja) 2016-06-30 2022-04-11 デュレクト コーポレーション デポー製剤
JP2020504182A (ja) * 2017-01-06 2020-02-06 パルヴェラ セラピューティクス エルエルシー ｍＴＯＲ阻害剤の無水組成物およびその使用方法
JP2022104987A (ja) * 2017-01-06 2022-07-12 パルヴェラ セラピューティクス、インク． ｍＴＯＲ阻害剤の無水組成物およびその使用方法
JP7108631B2 (ja) 2017-01-06 2022-07-28 パルヴェラ セラピューティクス、インク． ｍＴＯＲ阻害剤の無水組成物およびその使用方法
JP7416849B2 (ja) 2017-01-06 2024-01-17 パルヴェラ セラピューティクス、インク． ｍＴＯＲ阻害剤の無水組成物およびその使用方法
JP2024041830A (ja) * 2017-01-06 2024-03-27 パルヴェラ セラピューティクス、インク． ｍＴＯＲ阻害剤の無水組成物およびその使用方法
US12268673B2 (en) 2017-01-06 2025-04-08 Palvella Therapeutics, Inc. Anhydrous compositions of mTOR inhibitors and methods of use
JP7698749B2 (ja) 2017-01-06 2025-06-25 パルヴェラ セラピューティクス、インク． ｍＴＯＲ阻害剤の無水組成物およびその使用方法
JP2021530463A (ja) * 2018-07-02 2021-11-11 パルヴェラ セラピューティクス、インク． ｍＴＯＲ阻害剤の無水組成物および使用方法
WO2021132565A1 (ja) * 2019-12-26 2021-07-01 参天製薬株式会社 シロリムスまたはその塩を含有する水性懸濁組成物
JPWO2021132565A1 (enExample) * 2019-12-26 2021-07-01
JP7682103B2 (ja) 2019-12-26 2025-05-23 参天製薬株式会社 シロリムスまたはその塩を含有する水性懸濁組成物
RU2842860C1 (ru) * 2019-12-26 2025-07-02 Сантен Фармасьютикал Ко., Лтд. Водная суспензионная композиция, содержащая сиролимус или его соль

Also Published As

Publication number Publication date
CN101827523A (zh) 2010-09-08
EP2187743B1 (en) 2014-07-30
EP2187743A2 (en) 2010-05-26
EP2187743A4 (en) 2010-10-27
ES2507078T3 (es) 2014-10-14
WO2009023877A3 (en) 2009-04-09
WO2009023877A2 (en) 2009-02-19
KR20100055482A (ko) 2010-05-26

Similar Documents

Publication Publication Date Title
JP4974903B2 (ja) 疾患または状態を処置するための液体処方物
JP2010536797A (ja) 眼の疾患または状態を治療するための製剤
US8663639B2 (en) Formulations for treating ocular diseases and conditions
JP5528708B2 (ja) 安定な製剤ならびにそれらを調製および使用する方法
US20170049786A1 (en) Mtor pathway inhibitors for treating ocular disorders
JP2008533204A (ja) 病気又は症状の治療のためのドラッグ送達システム
CN101137370B (zh) 用于治疗疾病或病症的液体制剂
AU2012200274B2 (en) Liquid formulations for treatment of diseases or conditions
HK1117391A (en) Formulations for ocular treatment
HK1200365B (zh) 用於治疗疾病或病症的液体制剂

Legal Events

Date Code Title Description
A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20110531

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20110616

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20110616

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20130416

A524 Written submission of copy of amendment under article 19 pct

Free format text: JAPANESE INTERMEDIATE CODE: A524

Effective date: 20130610

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20130702

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20130918

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20131002

A912 Re-examination (zenchi) completed and case transferred to appeal board

Free format text: JAPANESE INTERMEDIATE CODE: A912

Effective date: 20131025